TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Early-stage Breast Cancer|High Risk Breast Carcinoma
Interventions: DRUG: Abemaciclib|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: LHRH Agonist
Sponsor: Dana-Farber Cancer Institute
Collaborators: Eli Lilly and Company